Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fayez G. Alruwaily"'
Autor:
Khalid Al-Rubeaan, Faisal A. Bana, Fayez G. Alruwaily, Eman Sheshah, Dhekra Alnaqeb, Awad M. AlQahtani, Diaa Ewais, Nassr Al Juhani, Abdul-hameed Hassan, Amira M. Youssef
Publikováno v:
Saudi Pharmaceutical Journal, Vol 28, Iss 3, Pp 329-337 (2020)
Objectives: The DISCOVER study is a global, prospective, three- year- observational (non-interventional) study that was conducted in 37 countries throughout the world including Saudi Arabia and aimed to assess variations in treatment patterns and the
Externí odkaz:
https://doaj.org/article/bbc78fcf809e4d53b244bbe6f915f5ef
Autor:
Amira M Youssef, Khalid Al Rubeaan, Faisal Banah, Fayez G Alruwaily, Eman Sheshah, Dhekra Alnaqeb, Awad M AlQahtani, Diaa Ewais, Nassr Al Juhani, Abdul-Hameed Hassan
Publikováno v:
BMJ Open, Vol 13, Iss 8 (2023)
Objectives The aim of the global DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings (DISCOVER) Study was to provide a comprehensive real world assessment of the treatment pattern changes for patients with type 2 diabetes. The aim
Externí odkaz:
https://doaj.org/article/a403c5435680425b94a62bd174cb958b
Autor:
Fayez G. Alruwaily, Awad M. AlQahtani, Amira M. Youssef, Dhekra AlNaqeb, Abdul-hameed Hassan, Khalid Al-Rubeaan, Faisal A. Bana, Eman Sheshah, Nassr Al Juhani, Diaa Ewais
Publikováno v:
Saudi Pharmaceutical Journal, Vol 28, Iss 3, Pp 329-337 (2020)
Saudi Pharmaceutical Journal : SPJ
Saudi Pharmaceutical Journal : SPJ
Objectives: The DISCOVER study is a global, prospective, three- year- observational (non-interventional) study that was conducted in 37 countries throughout the world including Saudi Arabia and aimed to assess variations in treatment patterns and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d6fc89760b73c4ca12c6182ff180c1
http://www.sciencedirect.com/science/article/pii/S1319016420300220
http://www.sciencedirect.com/science/article/pii/S1319016420300220
Autor:
Khalid, Al-Rubeaan, Faisal, Banah, Fayez G, Alruwaily, Eman, Sheshah, Dhekra, Alnaqeb, Awad M, AlQahtani, Diaa, Ewais, Nassr, Al Juhani, Abdul-Hameed, Hassan, Amira M, Youssef
Patients with type 2 diabetes nowadays have a wide range of new antidiabetic medications with better efficacy and safety. Physicians’ attitude toward selecting antidiabetic medications to reach targeted glycemic control and better quality of life (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3fc85ac24560d878de55f3b0c34b8d4
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 19
The molecular targeted therapy started with introduction of tyrosine kinase inhibitor (Imatinib) that selectively inhibit phosphorylation of BCR-ABL protein with subsequent inhibition of growth of BCR-ABL positive cells [1].
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43a75bdaddcf098e4eb5aedc64b3a35b
https://doi.org/10.26717/bjstr.2019.19.003233
https://doi.org/10.26717/bjstr.2019.19.003233